Page 83 - HIV/AIDS Guidelines

18. FoodandDrugAdministration.Edurant(packageinsert)
http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202022s000lbl.pdf.AccessedAug15,2011.2011.
19. FoodandDrugAdministration.Intelence(packageinsert).
http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022187s008lbl.pdf.AccessedMarch23,2012.
20. GazzardB,DuvivierC,ZaglerC,etal.Phase2double-blind,randomisedtrialofetravirineversusefavirenzin
treatment-naivepatients:48weekresults.AIDS.Nov282011;25(18)2249-2258.
21. CassettiI,MadrugaJV,EtzelA,al.e.ThesafetyandefficacyoftenofovirDF(TDF)incombinationwithlamivudine
(3TC)andefavirenz(EFV)inantiretroviral-naivepatientsthroughsevenyears.Paperpresentedat:17thInternational
AIDSConference;Aug.3-8,2008;MexicoCity,Mexico.
22. GulickRM,RibaudoHJ,ShikumaCM,etal.Triple-nucleosideregimensversusefavirenz-containingregimensforthe
initialtreatmentofHIV-1infection.N Engl J Med.Apr292004;350(18):1850-1861.
23. GallantJE,RodriguezAE,WeinbergWG,etal.Earlyvirologicnonresponsetotenofovir,abacavir,andlamivudinein
HIV-infectedantiretroviral-naivesubjects. J Infect Dis.Dec12005;192(11):1921-1930.
24. vanLethF,PhanuphakP,RuxrungthamK,etal.Comparisonoffirst-lineantiretroviraltherapywithregimensincluding
nevirapine,efavirenz,orbothdrugs,plusstavudineandlamivudine:arandomisedopen-labeltrial,the2NNStudy.
Lancet.Apr172004;363(9417):1253-1263.
25. NunezM,SorianoV,Martin-CarboneroL,etal.SENC(Spanishefavirenzvs.nevirapinecomparison)trial:a
randomized,open-labelstudyinHIV-infectednaiveindividuals.HIV Clin Trials.May-Jun2002;3(3):186-194.

26. FoodandDrugAdministration.Sustive(packageinsert).
http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021360s024lbl.pdf.AccessedMarch20,2012.

27. FundaroC,GenoveseO,RendeliC,TamburriniE,SalvaggioE.Myelomeningoceleinachildwithintrauterineexposure
toefavirenz.AIDS.Jan252002;16(2):299-300.

28. AntiretroviralPregnancyRegistrySteeringCommittee.AntiretroviralPregnancyRegistryinternationalinterimreportfor
1Jan1989-31January2007.2007;http://www.APRegistry.com.

29. CohenCJ,Andrade-VillanuevaJ,ClotetB,etal.Rilpivirineversusefavirenzwithtwobackgroundnucleosideor
nucleotidereversetranscriptaseinhibitorsintreatment-naiveadultsinfectedwithHIV-1(THRIVE):aphase3,
randomised,non-inferioritytrial.Lancet.Jul162011;378(9787):229-237.
30. MolinaJM,CahnP,GrinsztejnB,etal.Rilpivirineversusefavirenzwithtenofovirandemtricitabineintreatment-naive
adultsinfectedwithHIV-1(ECHO):aphase3randomiseddouble-blindactive-controlledtrial.Lancet.Jul16
2011;378(9787):238-246.
31. SorianoV,ArastehK,MigroneH,etal.Nevirapineversusatazanavir/ritonavir,eachcombinedwithtenofovirdisoproxil
fumarate/emtricitabine,inantiretroviral-naiveHIV-1patients:theARTENTrial.Antivir Ther.2011;16(3):339-348.
32. SanneI,Mommeja-MarinH,HinkleJ,etal.SeverehepatotoxicityassociatedwithnevirapineuseinHIV-infected
subjects.J Infect Dis.Mar152005;191(6):825-829.

33. BaylorMS,Johann-LiangR.Hepatotoxicityassociatedwithnevirapineuse.J Acquir Immune Defic Syndr. Apr15
2004;35(5):538-539.

34. BoehringerIngelheim.DearHealthCareProfessionalLetter:Clarificationofriskfactorsforsevere,life-threateningand
fatalhepatotoxicitywithVIRAMUNE®(nevirapine).February2004.

35. PetersP,StringerJ,McConnellMS,etal.Nevirapine-associatedhepatotoxicitywasnotpredictedbyCD4count≥250
cells/muLamongwomeninZambia,ThailandandKenya.HIV Med. Nov2010;11(10):650-660.

36. CoffiePA,Tonwe-GoldB,TanonAK,etal.Incidenceandriskfactorsofsevereadverseeventswithnevirapine-based
antiretroviraltherapyinHIV-infectedwomen.MTCT-Plusprogram,Abidjan,Coted'Ivoire.BMC Infect Dis.2010;10:188.
37. KesselringAM,WitFW,SabinCA,etal.Riskfactorsfortreatment-limitingtoxicitiesinpatientsstartingnevirapine-
containingantiretroviraltherapy.AIDS.Aug242009;23(13):1689-1699.

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents F-22

Downloaded from http://aidsinfo.nih.gov/guidelines on 12/8/2012 EST.